Imunon (IMNN) Competitors $0.92 +0.05 (+5.39%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.88 -0.04 (-4.13%) As of 02/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IMNN vs. KALA, CNTB, CELU, XLO, DYAI, ALVR, ATRA, OSTX, OVID, and NBRVShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include KALA BIO (KALA), Connect Biopharma (CNTB), Celularity (CELU), Xilio Therapeutics (XLO), Dyadic International (DYAI), AlloVir (ALVR), Atara Biotherapeutics (ATRA), OS Therapies (OSTX), Ovid Therapeutics (OVID), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. Imunon vs. KALA BIO Connect Biopharma Celularity Xilio Therapeutics Dyadic International AlloVir Atara Biotherapeutics OS Therapies Ovid Therapeutics Nabriva Therapeutics Imunon (NASDAQ:IMNN) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Does the media refer more to IMNN or KALA? In the previous week, Imunon had 4 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for Imunon and 0 mentions for KALA BIO. Imunon's average media sentiment score of 0.33 beat KALA BIO's score of 0.00 indicating that Imunon is being referred to more favorably in the media. Company Overall Sentiment Imunon Neutral KALA BIO Neutral Does the MarketBeat Community favor IMNN or KALA? KALA BIO received 281 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 66.89% of users gave KALA BIO an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes20100.00% Underperform VotesNo VotesKALA BIOOutperform Votes30166.89% Underperform Votes14933.11% Do analysts rate IMNN or KALA? Imunon presently has a consensus price target of $20.50, suggesting a potential upside of 2,130.69%. KALA BIO has a consensus price target of $15.00, suggesting a potential upside of 125.90%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in IMNN or KALA? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.0% of Imunon shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, IMNN or KALA? Imunon has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.03, indicating that its stock price is 303% less volatile than the S&P 500. Is IMNN or KALA more profitable? Imunon's return on equity of -230.05% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% KALA BIO N/A -448.61%-69.37% Which has preferable valuation and earnings, IMNN or KALA? Imunon has higher earnings, but lower revenue than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K26.65-$19.51M-$1.89-0.49KALA BIO$3.89M10.40-$42.20M-$12.47-0.53 SummaryImunon beats KALA BIO on 12 of the 17 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.33M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E Ratio-0.492.5616.5114.19Price / Sales26.65304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book0.656.717.644.63Net Income-$19.51M$138.11M$3.18B$245.69M7 Day Performance2.11%-2.54%-1.95%-2.68%1 Month Performance3.24%-2.00%-0.23%-2.16%1 Year Performance62.48%-5.04%16.69%12.90% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.3114 of 5 stars$0.92+5.4%$20.50+2,130.7%+70.2%$13.33M$500,000.00-0.4930Analyst ForecastNews CoverageGap UpKALAKALA BIO3.9589 of 5 stars$8.38+8.0%$15.00+79.0%-7.0%$51.03M$3.89M-0.6730CNTBConnect Biopharma2.9778 of 5 stars$0.92-4.9%$8.00+767.3%-24.3%$50.96MN/A0.00110CELUCelularity0.9873 of 5 stars$2.14+4.4%N/A-61.1%$50.95M$48.20M0.00220XLOXilio Therapeutics3.2532 of 5 stars$1.14-11.6%$4.00+250.9%+63.2%$50.11M$4.62M-0.6670High Trading VolumeDYAIDyadic International1.8014 of 5 stars$1.69flat$6.00+255.0%-2.0%$50.01M$2.90M-7.357Gap UpALVRAlloVir3.0322 of 5 stars$9.90+0.2%N/A-41.2%$49.80MN/A-0.49110Positive NewsATRAAtara Biotherapeutics4.3225 of 5 stars$8.59-1.5%$17.75+106.6%-64.3%$49.48M$8.57M-0.33330OSTXOS Therapies2.468 of 5 stars$2.23+12.1%$17.50+684.8%N/A$48.90MN/A0.00N/AAnalyst ForecastInsider TradeNews CoverageGap UpHigh Trading VolumeOVIDOvid Therapeutics4.5288 of 5 stars$0.64-0.3%$4.03+526.5%-82.7%$45.72M$390,000.00-1.3760NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies KALA Competitors CNTB Competitors CELU Competitors XLO Competitors DYAI Competitors ALVR Competitors ATRA Competitors OSTX Competitors OVID Competitors NBRV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts